Page last updated: 2024-12-08

taurochenodeoxycholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Taurochenodeoxycholic Acid: A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

taurochenodeoxycholate : An organosulfonate oxoanion that is the conjugate base of taurochenodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

taurochenodeoxycholic acid : A bile acid taurine conjugate of chenodeoxycholic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID387316
CHEMBL ID185878
CHEBI ID16525
SCHEMBL ID56780
SCHEMBL ID20261728
MeSH IDM0021066

Synonyms (55)

Synonym
CHEBI:16525 ,
taurine chenodeoxycholate
2-[(3alpha,7alpha-dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonic acid
NCI60_028900
LMST05040005
2-[(3a,7a-dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonate
n-(3alpha,7alpha-dihydroxy-5beta-cholan-24-oyl)-taurine
TUD ,
taurochenodeoxycholic acid
516-35-8
C05465
chenodeoxycholoyltaurine
taurochenodeoxycholate
chenodeoxycholyltaurine
c26h45no6s
ethanesulfonic acid, 2-(((3alpha,5beta,7alpha)-3,7-dihydroxy-24-oxocholan-24-yl)amino)-
tcdca
taurochenodesoxycholic acid
2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
2-[4-(3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoylamino]ethanesulfonic acid
CHEMBL185878 ,
taurochenodeoxycholic acid-d5 (major)
n-(3a,7a-dihydroxy-5b-cholan-24-oyl)-taurine
S3865
bdbm50375595
651ku15938 ,
chenyltaurine
unii-651ku15938
12-desoxycholyltaurine
12-deoxycholyltaurine
gtpl4747
2-[(4r)-4-[(1s,2s,5r,7s,9r,10r,11s,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]ethane-1-sulfonic acid
SCHEMBL56780
2-((r)-4-((3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic acid
2-([3alpha,7alpha-dihydroxy-24-oxo-5beta-cholan24-yl]amino)ethanesulfonic acid
AKOS025290383
st 24:1;o3;t
3.alpha.,7.alpha.-dihydroxy-n-(2-sulfoethyl)-5.beta.-cholan-24-amide
taurochenodesoxycholate
3a,7a-dihydroxy-n-(2-sulfoethyl)-5b-cholan-24-amide
HY-N2027
CS-6329
2-{[(3beta,5beta,7alpha,14beta,17alpha)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonic acid
DB08833
BS-16963
mfcd00232922
Q7688892
SCHEMBL20261728
HMS3885A10
CCG-269686
2-((r)-4-((3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonicacid
taurochenodeoxycholate, tcdca, 12-deoxycholyltaurine, chenodeoxycholyltaurine, chenyltaurine
DTXSID101020121
taurochenodesoxycholicacid
2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" When ursodeoxycholate (final concentration, 30 mumol/L or 100 mumol/L) was added to mitochondrial incubations containing chenodeoxycholate or lithocholate, the toxic effects of lipophilic bile acids on mitochondrial oxidative metabolism were partially reversed."( Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria.
Fischer, S; Krähenbühl, S; Reichen, J; Talos, C, 1994
)
0.29
" The cellular mechanism(s) of toxicity and nature of the AbetaE22Q toxic assemblies are not completely understood."( Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells.
Castro, RE; Fossati, S; Ghiso, J; Meyerson, J; Nunes, AF; Ramalho, RM; Rodrigues, CM; Rostagno, A; Viana, RJ, 2009
)
0.35
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36
" Based on the analysis using principle components analysis (PCA), toxic groups could be distinguished from their control groups, which suggested that the variance of the contents of bile acids could evaluate hepatotoxicity caused by ET and DB."( [Evaluation on hepatotoxicity caused by Dioscorea bulbifera based on analysis of bile acids].
Chen, CC; Hu, ZB; Ji, LL; Wang, JM; Wang, ZT; Xu, Y; Yang, L, 2011
)
0.37
" It is suggested that TUDCA therapy is safe and appears to be more effective than UDCA in the treatment of liver cirrhosis, particularly in the improvement of the biochemical expression."( Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial.
Hou, XH; Li, AH; Li, L; Pan, XL; Xu, KS; Yang, L; Ye, J; Zhao, L, 2013
)
0.39
" Supplementation with UDCA in the absence of Bsep caused adverse effects in abcb11-/- mice."( Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Forrest, D; Hagey, LR; Hofmann, AF; Ling, V; Liu, L; Sheps, JA; Wang, R, 2013
)
0.39
"2,4-Dichlorophenol (2,4-DCP) is an environmental pollutant exhibiting a wide spectrum of toxic effects."( Endoplasmic reticulum stress is involved in 2,4-dichlorophenol-induced hepatotoxicity.
Chen, P; Fu, J; Zhang, X; Zhang, Y, 2016
)
0.43
" Both drugs were well tolerated, with comparable adverse event rates between the 2 groups."( A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.
Chen, C; Chen, G; Chen, M; Cheng, L; Duan, L; Fu, X; Gao, Z; Han, Y; Hu, H; Jia, J; Ma, H; Miao, X; Ning, Q; Sheng, J; Shi, G; Tang, H; Wang, G; Wang, J; Wei, L; Wu, S; Xie, Q; Xie, W; Xu, J; Yan, H; Yao, C; Zeng, M; Zhu, Y, 2016
)
0.43
"TUDCA is safe and as efficacious as UDCA for the treatment of PBC, and may be better to relieve symptoms than UDCA."( A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.
Chen, C; Chen, G; Chen, M; Cheng, L; Duan, L; Fu, X; Gao, Z; Han, Y; Hu, H; Jia, J; Ma, H; Miao, X; Ning, Q; Sheng, J; Shi, G; Tang, H; Wang, G; Wang, J; Wei, L; Wu, S; Xie, Q; Xie, W; Xu, J; Yan, H; Yao, C; Zeng, M; Zhu, Y, 2016
)
0.43
"It has been well established that HMG-CoA reductase inhibitors (statins) cause adverse side effects in skeletal muscle ranging from mild to fatal myotoxicity upon dose, drug interaction, and exercise."( C/EBP homologous protein deficiency inhibits statin-induced myotoxicity.
Han, JH; Kim, S; Kim, SY; Kim, WH; Lee, CH; Lim, JH; Park, KM; Shin, DS; Woo, CH, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" One hundred milimoles solution of TCA had 2-fold activity of a 25mM solution in the dissolution of both the slices and the whole concrement when it was used in combination with EDTA 4Na."( [Effect of proteolytic enzymes and bile salts combined with EDTA 4Na on the dissolution of calcium bilirubinate gallstones].
Cho, H; Shinya, F; Suzuki, N; Takahashi, W, 1987
)
0.27
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The effectiveness of ursodeoxycholic acid in treating biliary liver diseases is limited by low bioavailability and moderate activity."( Metabolism, pharmacokinetics, and activity of a new 6-fluoro analogue of ursodeoxycholic acid in rats and hamsters.
Cerrè, C; Forti, GC; Gioacchini, AM; Natalini, B; Pellicciari, R; Polimeni, C; Roda, A; Sadeghpour, B; Sapigni, E, 1995
)
0.29
"Cyclosporin A (CsA) exhibits poor bioavailability after oral administration of Sandimmune, with wide intra- and interindividual variations."( Effects of tauroursodeoxycholate solutions on cyclosporin A bioavailability in rats.
Balandraud-Pieri, N; Bertault-Pérès, P; Caroli-Bosc, FX; Durand, A; Montet, AM; Montet, JC; Queneau, PE, 1997
)
0.3
" Exercise induces AMPK activation and subsequent PPARδ activation, which help to reduce endoplasmic reticulum (ER) and oxidative stress, thus increasing NO bioavailability in endothelial cells and vascular tissues."( PPARδ Is Required for Exercise to Attenuate Endoplasmic Reticulum Stress and Endothelial Dysfunction in Diabetic Mice.
Cheang, WS; Chen, ZY; Huang, Y; Lau, CW; Ma, RC; Tian, XY; Wang, L; Wang, N; Wong, WT; Xu, A; Xu, J; Zhao, L, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" The livers and intestines were separately perfused and dose-response curves (0."( Hepatic uptake and intestinal absorption of bile acids in the rabbit.
Aldini, R; Cerre, C; Galletti, G; Lenzi, PL; Montagnani, M; Polimeni, C; Roda, A; Roda, E, 1994
)
0.29
" Dosage for both drugs was 10 mg/kg body weight daily."( [Tauro-ursodeoxycholic acid vs. ursodeoxycholic acid in the dissolution of biliary calculi. Results of a single blind study].
Chiandussi, L; De Micheli, AG; Gallo, V, 1993
)
0.29
"The therapeutic index of either taurocholate (TC) or tauroursodeoxycholate (TUDC) administration in the treatment of drug-induced cholestasis was evaluated in perfused rat liver using a dose-response study."( Therapeutic index of taurocholate or tauroursodeoxycholate in experimental drug-induced cholestasis.
Adinolfi, LE; Tripodi, MF; Utili, R,
)
0.13
" We performed a dose-response study on 24 patients with primary biliary cirrhosis who were randomly assigned to receive 500, 1000, or 1500 mg daily of tauroursodeoxycholic acid for six months."( Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study.
Battezzati, PM; Covini, G; Crosignani, A; Invernizzi, P; Podda, M; Setchell, KD; Zuin, M, 1996
)
0.29
" These results can be used as guidelines to assess the required daily dosage of TUDCA."( Effect of tauroursodeoxycholic acid (TUDCA) on biliary lipid composition.
Cianci, V; Liu, XT; Muraca, M; Vilei, MT,
)
0.13
"A dose-response study of bolus intravenous (i."( Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat.
Devereaux, MW; Everson, G; Goff, MC; Han, D; McKim, JM; Packer, L; Ruyle, SZ; Sokol, RJ, 1998
)
0.53
" We determined that a minimum period of 15 days of treatment with a 8 mg/Kg/day dosage resulted in fibril removal."( Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models.
Cardoso, I; Martins, D; Merlini, G; Ribeiro, T; Saraiva, MJ, 2010
)
0.36
"At peak postnatal hyperbilirubinemia, j/j Gunn rat pups were dosed with sulfadimethoxine to induce bilirubin encephalopathy."( Lipid peroxidation is not the primary mechanism of bilirubin-induced neurologic dysfunction in jaundiced Gunn rat pups.
Daood, MJ; Hoyson, M; Watchko, JF, 2012
)
0.38
" Results showed that TUDCA pretreatment (once daily for 7 consecutive days) at the dosage of 200 and 400 mg/kg, but not 100 mg/kg, markedly attenuated LPS (0."( Tauroursodeoxycholic Acid Ameliorates Lipopolysaccharide-Induced Depression Like Behavior in Mice via the Inhibition of Neuroinflammation and Oxido-Nitrosative Stress.
Chen, Z; Cheng, L; Huang, C, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
bile acid taurine conjugateA bile acid conjugate resulting from the formal condensation of a bile acid with the amino group of taurine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Bile Acid Biosynthesis1761
Congenital Bile Acid Synthesis Defect Type II1761
Congenital Bile Acid Synthesis Defect Type III1761
Familial Hypercholanemia (FHCA)1761
Zellweger Syndrome1761
Cerebrotendinous Xanthomatosis (CTX)1761
27-Hydroxylase Deficiency1761
Disorders of bile acid synthesis and biliary transport1840
Trans-sulfuration, one-carbon metabolism and related pathways053
One-carbon metabolism and related pathways038
Glucose homeostasis021

Protein Targets (11)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)55.00000.20005.677410.0000AID681389
Bile salt export pumpHomo sapiens (human)Ki28.00007.00008.25009.5000AID679472
Ileal sodium/bile acid cotransporterHomo sapiens (human)Ki6.10003.30006.400010.0000AID681332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)11.26330.02372.52598.9000AID1261245; AID1261246; AID324923
Bile acid receptorHomo sapiens (human)EC50 (µMol)3.00000.00401.419110.0000AID72525
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A4Rattus norvegicus (Norway rat)Km12.00000.24003.28416.5300AID681364
Bile salt export pumpRattus norvegicus (Norway rat)Km2.20002.20005.35007.5000AID678843
Solute carrier organic anion transporter family member 1A5Rattus norvegicus (Norway rat)Km7.00004.30006.39608.8000AID681360
Bile salt export pumpHomo sapiens (human)Km4.80004.25004.52504.8000AID680159
Sodium/bile acid cotransporterRattus norvegicus (Norway rat)Km5.00003.70005.36677.4000AID679119
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Km5.95000.01503.49967.0000AID681607; AID682135
Bile salt export pumpMus musculus (house mouse)Km5.70005.70005.70005.7000AID679642
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (86)

Processvia Protein(s)Taxonomy
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
sodium ion transportIleal sodium/bile acid cotransporterHomo sapiens (human)
response to bacteriumIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportIleal sodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportIleal sodium/bile acid cotransporterHomo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activityIleal sodium/bile acid cotransporterHomo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
microvillusIleal sodium/bile acid cotransporterHomo sapiens (human)
apical plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay IDTitleYearJournalArticle
AID1261246Agonist activity at wild type human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID167640The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 25%1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Specific inhibitors of ileal bile acid transport.
AID681539TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 17 uM, TCDC: 100 uM) in Xenopus laevis oocytes1991Proceedings of the National Academy of Sciences of the United States of America, Dec-01, Volume: 88, Issue:23
Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID167720Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID681332TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells1998The American journal of physiology, 01, Volume: 274, Issue:1
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
AID682135TP_TRANSPORTER: uptake in Oatp1-expressing CHO-03 cell1999The American journal of physiology, 04, Volume: 276, Issue:4
Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells.
AID680020TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.2 uM, TCDC: 100 uM) in Xenopus laevis oocytes1996Journal of hepatology, Nov, Volume: 25, Issue:5
Multispecific amphipathic substrate transport by an organic anion transporter of human liver.
AID680046TP_TRANSPORTER: uptake of Taurochenodeoxycholate at 20 u M in Oatp1-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID680001TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, TCDC: 100 uM) in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID680253TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 20 uM, TCDC: 200 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID681659TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 5 uM, TCDC: 50 uM) in membrane vesicles isolated from Bsep-expressing Balb-3T3 cells2000Gene, Jan-04, Volume: 241, Issue:1
Molecular cloning and characterization of the murine bile salt export pump.
AID165380The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 50%1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Specific inhibitors of ileal bile acid transport.
AID679472TP_TRANSPORTER: competitive inhibition of Taurocholate uptake in membrane vesicles prepared from High Five cells infected with the ABCB11 baculovirus2002Gastroenterology, Nov, Volume: 123, Issue:5
The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.
AID1261245Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID167719Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system.
AID681361TP_TRANSPORTER: uptake in Oatp3-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID681364TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Gastroenterology, Sep, Volume: 117, Issue:3
Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver.
AID680028TP_TRANSPORTER: inhibition of DHEAS uptake (DHEAS: 5 uM, TCDC: 100 uM) in Xenopus laevis oocytes1998FEBS letters, Mar-13, Volume: 424, Issue:3
Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID680006TP_TRANSPORTER: inhibition of Ouabain uptake (Ouabain: 100 uM, TCDC: 100 uM) in Xenopus laevis oocytes1996Journal of hepatology, Nov, Volume: 25, Issue:5
Multispecific amphipathic substrate transport by an organic anion transporter of human liver.
AID679569TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, TCDC: 100 uM) in Xenopus laevis oocytes1994The Journal of clinical investigation, Mar, Volume: 93, Issue:3
Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter.
AID681901TP_TRANSPORTER: inhibition of Taurocholate uptake by Taurochenodeoxycholate at a concentration of 20uM in membrane vesicles from MRP4-expressing V79 cells2003Hepatology (Baltimore, Md.), Aug, Volume: 38, Issue:2
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
AID681389TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells2003The Biochemical journal, Apr-15, Volume: 371, Issue:Pt 2
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4).
AID679934TP_TRANSPORTER: inhibition of Rhodamine 123 efflux (R123: 5 ug/mL, TCDC: 200 uM) in P1(0.5) cells1994Hepatology (Baltimore, Md.), Jul, Volume: 20, Issue:1 Pt 1
Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles.
AID680630TP_TRANSPORTER: inhibition of BSP uptake (BSP: 2 uM, TCDC: 100 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID681352TP_TRANSPORTER: transepithelial transport (basal to apical) in Ntcp/Bsep double transfected MDCK cell2005American journal of physiology. Gastrointestinal and liver physiology, Jan, Volume: 288, Issue:1
Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump.
AID678843TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells2000Gastroenterology, Feb, Volume: 118, Issue:2
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.
AID167721Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system.
AID681360TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID680581TP_TRANSPORTER: inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 uM, TCDC: 500.0 uM) in membrane vesicles from MRP3-expressing Sf9 cells2003The Biochemical journal, Jan-01, Volume: 369, Issue:Pt 1
Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.
AID680033TP_TRANSPORTER: inhibition of BSP uptake (BSP: 10 uM, TCDC: 100 uM) in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID165385The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 75%1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Specific inhibitors of ileal bile acid transport.
AID681458TP_TRANSPORTER: inhibition of Daunomycin uptake (Daunorubicin: 10 uM, TCDC: 200 uM) in canalicular membrane vesicles from SD rat1994Hepatology (Baltimore, Md.), Jul, Volume: 20, Issue:1 Pt 1
Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles.
AID1261228Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 50 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID681602TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997Hepatology (Baltimore, Md.), Dec, Volume: 26, Issue:6
Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver.
AID680582TP_TRANSPORTER: inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 uM, TCDC: 500 uM) by Taurochenodeoxycholate at a concentration of 500uM in membrane vesicle from MRP3-expressing Sf9 cells2003The Biochemical journal, Jan-01, Volume: 369, Issue:Pt 1
Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.
AID680159TP_TRANSPORTER: uptake in membrane vesicles isolated from Bsep-expressing Sf9 cells2002Gastroenterology, Nov, Volume: 123, Issue:5
Functional expression of the canalicular bile salt export pump of human liver.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID679642TP_TRANSPORTER: uptake in membrane vesicles isolated from Bsep-expressing Sf9 cells2001Hepatology (Baltimore, Md.), May, Volume: 33, Issue:5
Characterization of the mouse bile salt export pump overexpressed in the baculovirus system.
AID681349TP_TRANSPORTER: uptake in ASBT-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID679119TP_TRANSPORTER: uptake in Ntcp-expressing CHO cells1998The American journal of physiology, 02, Volume: 274, Issue:2
Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells.
AID681136TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells1999Molecular pharmacology, Apr, Volume: 55, Issue:4
Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID72525Binding affinity for Farnesoid X Receptor (FXR)2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (842)

TimeframeStudies, This Drug (%)All Drugs %
pre-199081 (9.62)18.7374
1990's171 (20.31)18.2507
2000's150 (17.81)29.6817
2010's324 (38.48)24.3611
2020's116 (13.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.21 (24.57)
Research Supply Index6.80 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index72.10 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (3.09%)5.53%
Reviews26 (2.98%)6.00%
Case Studies1 (0.11%)4.05%
Observational0 (0.00%)0.25%
Other819 (93.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]